Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on medical record review, staff interview, and policy and procedure review, the facility failed to ensure adequate monitoring of psychotropic medications for 5 of 5 sample residents (#2, #4, #5, #41, #56) reviewed for unnecessary medications. The findings were:1. Review of the quarterly MDS assessment dated [DATE] showed resident #41 had a BIMS score of 11 out 15, which indicated moderate cognitive impairment, and diagnoses which included anxiety disorder and depression. Further review showed the resident displayed no behaviors and received antidepressant and hypnotic medication. Review of the physician orders showed the resident received temazepam (hypnotic) 7.5 milligrams (mg) by mouth daily at bedtime for insomnia and duloxetine (antidepressant) 40 mg by mouth twice per day for major depressive disorder. Review of the antidepressant medication care plan, last revised on 3/31/26 showed interventions which included Monitor/Document side effects and effectiveness Q [every] shift. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified or monitored for the use of temazepam or duloxetine.
2. Review of the admission MDS assessment dated [DATE] showed resident #2 had a BIMS score of 12 out of 15, which indicated the resident was cognitively intact, and diagnoses which included depression. Further review showed the resident displayed no behaviors and received antidepressant medication. Review of the physician orders showed the resident received duloxetine (antidepressant) 20 mg mouth daily for rheumatoid arthritis and depressive disorders and trazadone (antidepressant) 50 mg by mouth daily for insomnia. Review of the antidepressant medication care plan, last revised on 1/27/26 showed interventions which included Monitor/Document side effects and effectiveness Q shift. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified or monitored for the use of duloxetine or trazadone.
3. Review of the medical record showed resident #56 admitted to the facility on [DATE] with diagnoses which included depression. Review of the physician's orders showed the resident received Adderall (amphetamine-dextroamphetamine) 20 mg by mouth twice a day for hypoactivity with major depressive disorder and fluoxetine (antidepressant) 80 mg by mouth daily for depression. Review of the antidepressant medication care plan, last revised on 4/2/26 showed interventions which included Monitor/Document side effects and effectiveness Q shift. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified or monitored for the use of Adderall or fluoxetine.
4. Review of the annual MDS assessment dated [DATE] showed resident #4 had a BIMS score of 6 out of 15, which indicated the resident was severely cognitively impaired, and had diagnoses which included non-Alzheimer's dementia, anxiety disorder, and depression. Further review showed the resident received antipsychotic and antianxiety medications. Review of the physician orders showed the resident received brexpiprazole (antipsychotic) 0.5 mg every evening by mouth for agitation, lorazepam (antianxiety) 0.5 mg twice daily for agitation and anxiety, and 0.5 mg lorazepam by mouth as needed every 3 hours for agitation and anxiety. Review of the antipsychotic medication care plan, last revised on 12/16/25 showed interventions which included Monitor behaviors of yelling out, cursing at staff, or sexually inappropriate comments. Document observed behavior and attempted interventions. The following concern was identified:
a. Review of the medical record showed there were no medication specific target symptoms identified for the lorazepam.
5. Review of the MDS assessment dated [DATE] showed resident #5 had short-term and long-term memory impairment and had diagnoses which included non-Alzheimer's dementia, depression, and bipolar disorder. Further review showed the resident received antipsychotic and antidepressant medications. Review of the physician orders showed the resident received bupropion (antidepressant) 150 mg by mouth daily for major depressive disorder, fluoxetine (antidepressant) 20 mg daily by mouth for bipolar disorder, and olanzapine (antipsychotic) 5 mg daily at bedtime for bipolar disorder. Review of the antidepressant medication care plan, last revised 5/2/25 showed interventions which included Monitor/document for side effects and effectiveness. Review of the antipsychotic medication care plan, last revised 5/2/25, showed interventions which included monitor for side effects and effectiveness. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified for the Bupropion, fluoxetine, or olanzapine.
6. Interview with the DON, SSD, SDC, LPN #1, and the pharmacist on 4/9/26 at 9:01 AM confirmed the facility did not identify or monitor resident or medication specific target symptoms for psychotropic medications.
7. Review of the policy titled Psychotropic Medications provided by the facility on 4/9/26 showed An unnecessary drug is any drug when used . (3) Without adequate monitoring .
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified or monitored for the use of temazepam or duloxetine.
2. Review of the admission MDS assessment dated [DATE] showed resident #2 had a BIMS score of 12 out of 15, which indicated the resident was cognitively intact, and diagnoses which included depression. Further review showed the resident displayed no behaviors and received antidepressant medication. Review of the physician orders showed the resident received duloxetine (antidepressant) 20 mg mouth daily for rheumatoid arthritis and depressive disorders and trazadone (antidepressant) 50 mg by mouth daily for insomnia. Review of the antidepressant medication care plan, last revised on 1/27/26 showed interventions which included Monitor/Document side effects and effectiveness Q shift. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified or monitored for the use of duloxetine or trazadone.
3. Review of the medical record showed resident #56 admitted to the facility on [DATE] with diagnoses which included depression. Review of the physician's orders showed the resident received Adderall (amphetamine-dextroamphetamine) 20 mg by mouth twice a day for hypoactivity with major depressive disorder and fluoxetine (antidepressant) 80 mg by mouth daily for depression. Review of the antidepressant medication care plan, last revised on 4/2/26 showed interventions which included Monitor/Document side effects and effectiveness Q shift. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified or monitored for the use of Adderall or fluoxetine.
4. Review of the annual MDS assessment dated [DATE] showed resident #4 had a BIMS score of 6 out of 15, which indicated the resident was severely cognitively impaired, and had diagnoses which included non-Alzheimer's dementia, anxiety disorder, and depression. Further review showed the resident received antipsychotic and antianxiety medications. Review of the physician orders showed the resident received brexpiprazole (antipsychotic) 0.5 mg every evening by mouth for agitation, lorazepam (antianxiety) 0.5 mg twice daily for agitation and anxiety, and 0.5 mg lorazepam by mouth as needed every 3 hours for agitation and anxiety. Review of the antipsychotic medication care plan, last revised on 12/16/25 showed interventions which included Monitor behaviors of yelling out, cursing at staff, or sexually inappropriate comments. Document observed behavior and attempted interventions. The following concern was identified:
a. Review of the medical record showed there were no medication specific target symptoms identified for the lorazepam.
5. Review of the MDS assessment dated [DATE] showed resident #5 had short-term and long-term memory impairment and had diagnoses which included non-Alzheimer's dementia, depression, and bipolar disorder. Further review showed the resident received antipsychotic and antidepressant medications. Review of the physician orders showed the resident received bupropion (antidepressant) 150 mg by mouth daily for major depressive disorder, fluoxetine (antidepressant) 20 mg daily by mouth for bipolar disorder, and olanzapine (antipsychotic) 5 mg daily at bedtime for bipolar disorder. Review of the antidepressant medication care plan, last revised 5/2/25 showed interventions which included Monitor/document for side effects and effectiveness. Review of the antipsychotic medication care plan, last revised 5/2/25, showed interventions which included monitor for side effects and effectiveness. The following concern was identified:
a. Review of the medical record showed there were no resident specific or medication specific target symptoms identified for the Bupropion, fluoxetine, or olanzapine.
6. Interview with the DON, SSD, SDC, LPN #1, and the pharmacist on 4/9/26 at 9:01 AM confirmed the facility did not identify or monitor resident or medication specific target symptoms for psychotropic medications.
7. Review of the policy titled Psychotropic Medications provided by the facility on 4/9/26 showed An unnecessary drug is any drug when used . (3) Without adequate monitoring .